Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07733219 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Multicentre Phase II Trial Evaluating Stereotactic Body Radiotherapy on Ultra-central Lung Tumors on MR-Linac

Study acronym: LIN-LUNG-2504
StatusNot Yet Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Centre Oscar Lambret
100 trials monitored
See 2 trials at risk
Lung Cancer
4,790 trials monitored
See 263 trials at risk
Phase II multicenter trial evaluating the safety, tolerability, and feasibility of MRI-guided stereotactic radiotherapy using MRI-LINAC in patients with ultracentral lung tumors or lymphadenopathy in the context of controlled oligometastatic disease. The study investigates the potential of this innovative technology, which enables real-time treatment adaptation, with the goal of optimizing the benefit-risk ratio in a population at high risk of radiotherapy-related toxicity
Trial Details
NCT Number NCT07733219
Lead Sponsor Centre Oscar Lambret
Collaborators: Aquilab SAS, Centre François Baclesse (CTD-CNO)
Conditions
(from sponsor)		 Ultracentral Pulmonary Tumors, Lung Cancer (T1 N0 M0 and T2 N0 M0), Mediastinal Lymph Node Recurrence From All Types of Primary Cancer, Pulmonary Node Recurrence From All Types of Primary Cancer
Related terms Lung Neoplasms
Enrollment 59 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov